Takeda to divest consumer healthcare business to Blackstone for $2.3bn
Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The ... Read More
Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former's COVID‑19 vaccine candidate, in Japan. ... Read More
Takeda gets extended EC approval for ADCETRIS in sALCL
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More
Takeda Pharmaceutical to sell OTC and non-core products to Orifarm
Japan-based Takeda Pharmaceutical has agreed to sell a portfolio of 110 non-core over-the-counter (OTC) and prescription pharmaceutical products it sells in Europe along with a ... Read More
Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics
Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth ... Read More
ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib
ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase ... Read More
Takeda Pharmaceutical opens €130m vaccine manufacturing plant in Germany
Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine ... Read More
EC approves ADCETRIS for treating CD30+ Stage IV Hodgkin lymphoma
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical's ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV ... Read More
Takeda’s $62bn acquisition of Shire: A game-changing move for global pharma
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish biotech leader specializing in rare diseases, for ... Read More
PvP Biologics launches Phase 1 trials for celiac disease candidate Kuma062
PvP Biologics, a US-based pharmaceutical company, has recently begun two phase 1 clinical trials to assess the safety, tolerability, and pharmacodynamics of Kuma062, a promising ... Read More